{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T20:28:31Z","timestamp":1774124911840,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.3816\/clc.2006.s.011","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T21:02:25Z","timestamp":1221166945000},"page":"S31-S35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"S1","title":["Interstitial Lung Disease Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Non\u2013Small-Cell Lung Carcinoma"],"prefix":"10.3816","volume":"8","author":[{"given":"Ken Y.","family":"Yoneda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly A.","family":"Hardin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Gandara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David K.","family":"Shelton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLC.2006.s.011_bib1","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1093\/emboj\/19.13.3159","article-title":"The ErbB signaling network: receptor heterodimerization in development and cancer","volume":"19","author":"Olayioye","year":"2000","journal-title":"Embo J"},{"key":"10.3816\/CLC.2006.s.011_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0014-4827(02)00098-8","article-title":"Epidermal growth factor receptor: mechanisms of activation and signalling","volume":"284","author":"Jorissen","year":"2003","journal-title":"Exp Cell Res"},{"key":"10.3816\/CLC.2006.s.011_bib3","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0092-8674(02)00966-2","article-title":"Ligand-induced, receptor-mediated dimerization and activation of EGF receptor","volume":"110","author":"Schlessinger","year":"2002","journal-title":"Cell"},{"key":"10.3816\/CLC.2006.s.011_bib4","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","article-title":"Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]","volume":"21","author":"Fukuoka","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2006.s.011_bib5","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","article-title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial","volume":"290","author":"Kris","year":"2003","journal-title":"JAMA"},{"key":"10.3816\/CLC.2006.s.011_bib6","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib in patients with non\u2013small-cell lung cancer","volume":"22","author":"Perez-Soler","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2006.s.011_bib7","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)","volume":"366","author":"Thatcher","year":"2005","journal-title":"Lancet"},{"key":"10.3816\/CLC.2006.s.011_bib8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"10.3816\/CLC.2006.s.011_bib9","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/01.cad.0000127666.12215.7b","article-title":"Acute lung injury as an adverse event of gefitinib","volume":"15","author":"Inomata","year":"2004","journal-title":"Anticancer Drugs"},{"key":"10.3816\/CLC.2006.s.011_bib10","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1200\/JCO.2004.08.001","article-title":"Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial\u2013INTACT 1","volume":"22","author":"Giaccone","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2006.s.011_bib11","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2004.07.215","article-title":"Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial\u2013INTACT 2","volume":"22","author":"Herbst","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2006.s.011_bib12","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1158\/1078-0432.CCR-03-0564","article-title":"United States Food and Drug Administration Drug approval summary: gefitinib (ZD1839; Iressa) tablets","volume":"10","author":"Cohen","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLC.2006.s.011_bib13","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.2165\/00002018-200427140-00002","article-title":"Overview of the tolerability of gefitinib (IRESSA) monotherapy: clinical experience in non-small-cell lung cancer","volume":"27","author":"Forsythe","year":"2004","journal-title":"Drug Saf"},{"key":"10.3816\/CLC.2006.s.011_bib14","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1200\/JCO.2005.02.840","article-title":"TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer","volume":"23","author":"Herbst","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2006.s.011_bib15","first-page":"617","article-title":"Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced nonsmall cell cancer (NSCLC)","volume":"23","author":"Gatzemeier","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CLC.2006.s.011_bib16","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.1200\/JCO.2005.05.030","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out?","volume":"23","author":"Gandara","year":"2005","journal-title":"J Clin Oncol"},{"issue":"suppl 18","key":"10.3816\/CLC.2006.s.011_bib17","first-page":"381s","article-title":"Independent review of fatal interstitial lung disease (ILD) in TRIBUTE: paclitaxel + carboplatin \u00b1 erlotinib in advanced non-small cell lung cancer (NSCLC)","volume":"24","author":"Gandara","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2006.s.011_bib18","first-page":"628","article-title":"Cigarette smoking history predicts sensitivity to erlotinib: results of a phase II trial in patients with bronchoalveolar carcinoma (BAC)","volume":"23","author":"Kris","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CLC.2006.s.011_bib19","first-page":"633","article-title":"Preliminary results from a phase II study of the EGFR tyrosine kinase inhibitor erlotinib in patients >70 years of age with previously untreated advanced non-small cell lung carcinoma","volume":"23","author":"Johnson","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CLC.2006.s.011_bib20","first-page":"91","article-title":"Interstitial lung disease with epidermal growth factor receptor inhibitors in NSCLC","volume":"8","author":"Ranganathan","year":"2006","journal-title":"Clin Lung Cancer"},{"key":"10.3816\/CLC.2006.s.011_bib21","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1200\/JCO.2005.04.9866","article-title":"Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib","volume":"24","author":"Ando","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2006.s.011_bib22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.lungcan.2004.01.010","article-title":"Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib","volume":"45","author":"Takano","year":"2004","journal-title":"Lung Cancer"},{"key":"10.3816\/CLC.2006.s.011_bib23","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1634\/theoncologist.8-4-303","article-title":"FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets","volume":"8","author":"Cohen","year":"2003","journal-title":"Oncologist"},{"key":"10.3816\/CLC.2006.s.011_bib24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1634\/theoncologist.10-7-461","article-title":"FDA drug approval summary: erlotinib (Tarceva) tablets","volume":"10","author":"Cohen","year":"2005","journal-title":"Oncologist"},{"key":"10.3816\/CLC.2006.s.011_bib25","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.lungcan.2006.02.002","article-title":"Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group","volume":"52","author":"Endo","year":"2006","journal-title":"Lung Cancer"},{"issue":"suppl 2","key":"10.3816\/CLC.2006.s.011_bib26","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/sj.bjc.6602063","article-title":"Interstitial lung disease associated with drug therapy","volume":"91","author":"Camus","year":"2004","journal-title":"Br J Cancer"},{"key":"10.3816\/CLC.2006.s.011_bib27","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0169-5002(03)00043-6","article-title":"Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer","volume":"40","author":"Okamoto","year":"2003","journal-title":"Lung Cancer"},{"key":"10.3816\/CLC.2006.s.011_bib28","first-page":"415","article-title":"Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergy","volume":"25","author":"Aoe","year":"2005","journal-title":"Anticancer Res"},{"key":"10.3816\/CLC.2006.s.011_bib29","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1200\/JCO.2005.04.055","article-title":"Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis","volume":"23","author":"Nagaria","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLC.2006.s.011_bib30","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.2169\/internalmedicine.42.1022","article-title":"An autopsy case of acute pulmonary toxicity associated with gemcitabine","volume":"42","author":"Maniwa","year":"2003","journal-title":"Intern Med"},{"key":"10.3816\/CLC.2006.s.011_bib31","first-page":"977","article-title":"Alveolar hemorrhage as a possible adverse drug reaction by gefitinib (ZD1839, Iressa) [in Japanese]","volume":"30","author":"Ieki","year":"2003","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.3816\/CLC.2006.s.011_bib32","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1053\/crad.2001.0792","article-title":"Drug-induced lung disease: high-resolution CT and histological findings","volume":"57","author":"Cleverley","year":"2002","journal-title":"Clin Radiol"},{"key":"10.3816\/CLC.2006.s.011_bib33","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1056\/NEJMoa062200","article-title":"Comparison of two fluid-management strategies in acute lung injury","volume":"354","author":"National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS)","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLC.2006.s.011_bib34","unstructured":"Yoneda K. Interstitial lung disease (ILD) with EGFR TKIs. Presented at: 7th International Lung Cancer Congress (Workshop). June 28-July 1, 2006. Maui, HI."}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573041170537X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573041170537X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:00:34Z","timestamp":1761505234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152573041170537X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":34,"alternative-id":["S152573041170537X"],"URL":"https:\/\/doi.org\/10.3816\/clc.2006.s.011","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2006,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interstitial Lung Disease Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Non\u2013Small-Cell Lung Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CLC.2006.s.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}